Loading company…
MDxHealth is an Irvine, California-based provider of molecular diagnostic tests for prostate cancer and urinary tract infections.
Founded in 2003 and based in California, US, MDxHealth, Inc. develops molecular diagnostics for urologic oncology, including SelectMDx, a urine test for aggressive prostate cancer risk before biopsy, ConfirmMDx for post-biopsy tissue testing and the Genomic Prostate Score for localized prostate cancer. Its ResolveMDx test guides therapy for urinary tract infections. In May 2024 OrbiMed Advisors provided USD 55 million in debt financing, with a further USD 45 million drawable under the facility, and CEO Michael K. McGarrity leads the company.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in